Business
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual Gen
About this update from Argenx Se
[{"type":"image","alt":"argenx SE","displaySize":"","headline":null,"caption":"argenx SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vn6RW8oK.55yql.o3A46Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97}},"lazy":false},{"type":"text","content":"March 20, 2026","length":14,"tagName":"p"},{"type":"text","content":"Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.","length":804,"tagName":"p"},{"type":"text","content":"AgendaIn addition to recurrent items on the agenda, such as the discussion and adoption of the 2025 annual accounts, an advisory vote on the company’s 2025 remuneration report, the discharge of the directors for their duties performed in 2025 and the authorization of the Board of Directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, the following changes to the Board of Directors are also proposed:","length":438,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Appointment of Karen Massey as executive director to the Board for a term of 4 years","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Tim Van Hauwermeiren as non-executive director to the Board for a term of 4 years","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Re-appointment of Ana Céspedes as non-executive director to the Board of Directors for a term of 4 years","l...